Format

Send to

Choose Destination
Int J Hematol. 2018 Dec;108(6):598-606. doi: 10.1007/s12185-018-2551-y. Epub 2018 Oct 23.

Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.

Author information

1
Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
2
Department of Clinical Laboratory Medicine, Bunkyo Gakuin University, Tokyo, Japan.
3
Department of Hematology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
4
Department of Hematology, Eiju General Hospital, Tokyo, Japan.
5
Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan. hharada@toyaku.ac.jp.
6
Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan. hharada@toyaku.ac.jp.

Abstract

Splicing factor gene mutations are found in 60-70% of patients with myelodysplastic syndromes (MDS). We investigated the effects of splicing factor gene mutations on the diagnosis, patient characteristics, and prognosis of MDS. A total of 106 patients with MDS were included. The percentage of patients with MDS with ring sideroblasts (14.15%) as per the 2017 WHO classification was significantly higher than that of patients with refractory anemia with ring sideroblasts (2.88%) as per the 2008 WHO classification (Pā€‰=ā€‰0.005). Splicing factor mutations were detected in 32 patients (13 SF3B1, 8 U2AF1, and 11 SRSF2), and the mutations were mutually exclusive. Significant differences were observed in the mean corpuscular volume, platelet count, bone marrow myeloid:erythroid ratio, and megakaryocyte count in patients with different mutations. SRSF2 mutations were associated with a high cumulative incidence of red blood cell transfusion dependence, while SF3B1 mutations were associated with a low cumulative incidence of platelet concentrate transfusion dependence. Presence of SF3B1 mutation was a significant univariate predictor of overall survival, but become nonsignificant in the multivariate model. Although many factors also could affect survival, these results suggest that splicing factor mutations contribute to distinct MDS phenotypes, including patient characteristics and clinical courses.

KEYWORDS:

Blood transfusion; Gene mutations; Myelodysplastic syndromes; Prognosis; RNA splicing factors

PMID:
30353274
DOI:
10.1007/s12185-018-2551-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center